Research Articles
Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine

https://doi.org/10.1002/jps.2600691105Get rights and content

Abstract

On the average, 0.6% of a dose of ketoprofen or naproxen or 1.2% of a dose of probenecid was found in the urine of normal male volunteers assayed immediately after its collection. Between ∼60 and 85% of the dose of these drugs can be excreted in the urine as conjugates, which rapidly hydrolyze at body temperature, at room temperature, and even during frozen storage, thereby regenerating the parent drug. Since urine collections involved sample retention in the bladder at 37° for collection intervals as long as 2–3 hr, the given percentages excreted unchanged probably are overestimates. It is possible that no unchanged ketoprofen, naproxen, or probenecid is excreted in urine. This study contrasts with previous reports of up to 50% of a dose of ketoprofen and 15–17% of doses of naproxen and probenecid being excreted in urine as the parent compound. Those reports probably reflect primarily the duration of frozen sample storage between collection and assay along with the urine collection schedules employed, the speed of the clinical procedures, and the analytical procedures used. Attention should be given to potential conjugate hydrolysis whenever the pharmacokinetics of carboxylic acids are studied.

References (13)

  • JefferiesT.M. et al.

    J. Chromatogr.

    (1979)
  • MelethilS. et al.

    J. Pharm. Sci.

    (1976)
  • UptonR.A. et al.

    J. Chromatogr.

    (1980)
  • CastegnaroE. et al.

    Farmaco

    (1974)
  • LewellenO.R.W. et al.

    Scand. J. Rheumatol., Suppl.

    (1976)
  • DelbarreF. et al.

    Scand. J. Rheumatol., Suppl.

    (1976)
There are more references available in the full text version of this article.

Cited by (108)

  • Occurrence, sources and environmental risk assessment of pharmaceuticals in the Sea of Marmara, Turkey

    2022, Science of the Total Environment
    Citation Excerpt :

    This is attributed to the rapid degradation of diclofenac and ketoprofen by photodegradation and biodegradation (Andreozzi et al., 2003; Baena-Nogueras et al., 2017; Koumaki et al., 2015; Matamoros et al., 2008; Osorio et al., 2012; Yamamoto et al., 2009). Naproxen is known to be excreted unchanged at 60% in the human urine (Upton et al., 1980) and is relatively persistent in the receiving environment (Kosjek et al., 2005). The lower concentration of naproxen, on the other hand, may contribute to its high biodegradability, which might be regarded as a possible drug removal route (Eslami et al., 2015; Tixier et al., 2003a).

  • A Retrospective Biopharmaceutical Analysis of >800 Approved Oral Drug Products: Are Drug Properties of Solid Dispersions and Lipid-Based Formulations Distinctive?

    2020, Journal of Pharmaceutical Sciences
    Citation Excerpt :

    A significantly lower percentage of both LBF and SD drugs were excreted in urine compared to the Others dataset. This is not unexpected as drugs excreted in the urine unchanged are typically highly water soluble whereas PWSDs require metabolism into metabolites which are likely more polar and readily excreted.86 However, a range of factors may influence the predictive ability of this property, including need for a bioavailability factor for orally delivered drugs coupled with the fact that that certain drugs or active metabolites may be excreted unchanged in bile not urine.49

  • Methods for elucidation of transformation pathways: Identification of intermediate products, chiral, and isotope-ratio mass spectrometry analysis

    2013, Comprehensive Analytical Chemistry
    Citation Excerpt :

    With respect to the transformation processes of drugs, metabolism in the human body commonly produces one or more metabolites that, for the sake of excretability, exhibit higher polarity than the parent compound. Depending on the pharmaceutical, metabolites can make up a large fraction in the mass balance of an administered drug upon excretion, and on the other hand, some drugs are for less amenable to metabolic clearance but are excreted unchanged [5,6]. Then, human pharmaceuticals enter wastewater treatment plants (WWTPs) where biodegradation processes can bring about mineralization or more frequently partial degradation, leading to structurally related compounds referred to as transformation products (TPs) [7].

View all citing articles on Scopus
View full text